楊晨光 尹緒愛
[摘要]目的 分析絕經(jīng)后宮頸上皮內(nèi)瘤變(CIN)及宮頸癌(CC)患者的臨床特點。方法 選取2010年12月~2017年8月安徽醫(yī)科大學(xué)附屬巢湖醫(yī)院收治的413例CIN及CC患者?;仡櫺苑治龌颊叩呐R床癥狀和液基薄層細(xì)胞檢測(TCT)結(jié)果。根據(jù)患者是否絕經(jīng),分為絕經(jīng)組和未絕經(jīng)組,分別為104、309例。結(jié)果 絕經(jīng)組與未絕經(jīng)組均以體檢發(fā)現(xiàn)宮頸病變?yōu)橹?,分別為53.8%(56/104),68.9%(213/309),兩組比較差異有統(tǒng)計學(xué)意義(χ2=7.798,P=0.005)。臨床癥狀方面,絕經(jīng)組與未絕經(jīng)組中陰道不規(guī)則流血、接觸性陰道出血的占比差異有統(tǒng)計學(xué)意義(35.6% vs. 12.6%,χ2=27.307,P<0.001;2.9% vs. 13.3%,χ2=8.814,P=0.003)。兩組的TCT結(jié)果提示低度鱗狀上皮內(nèi)病變(LSIL)、高度鱗狀上皮內(nèi)病變(HSIL)陽性率均偏低,分別為22.1%(23/104),24.9%(77/309),差異無統(tǒng)計學(xué)意義(χ2=0.333,P=0.564)。結(jié)論 絕經(jīng)后CIN及CC患者的臨床癥狀以陰道不規(guī)則流血為主,接觸性陰道出血少見。
[關(guān)鍵詞]絕經(jīng)后;宮頸上皮內(nèi)瘤變; 宮頸癌;篩查;臨床特點
[中圖分類號] R737.33 ? ? [文獻(xiàn)標(biāo)識碼] A ? ? [文章編號] 1674-4721(2019)9(b)-0069-04
Clinical characteristics of postmenopausal patients with cervical intraepithelial neoplasia and cervical cancer
YANG Chen-guang? ?YIN Xu-ai
Department of Obstetric and Gynecology, Chaohu Hospital Affiliated to Anhui Medical University, Anhui Province, Chaohu? ?238000, China
[Abstract] Objective To analyze the clinical characteristics of postmenopausal patients with cervical intraepithelial neoplasia (CIN) and cervical cancer (CC). Methods From December 2010 to August 2017, 413 cases of CIN and CC admitted by the Department of Gynaecology of Chaohu Hospital Affiliated to Anhui Medical University were selected. The clinical symptoms and thin-cytologic test (TCT) results of the enrolled patients were analyzed retrospectively. According to whether the patient was menopausal, it was divided into menopausal group and non-menopausal group, 104 and 309 cases respectively. Statistical analysis was performed using SPSS 24.0 software. Results Both the menopausal group and the unmenopausal group were mainly found cervical lesions by physical examination, 53.8% (56/104) and 68.9% (213/309), respectively, and the difference between the two groups was statistically significant (χ2=7.798, P=0.005). In terms of clinical symptoms, the proportion of irregular vaginal bleeding and contact vaginal bleeding in the menopausal group and the unmenopausal group was significantly different and statistically significant (35.6% vs. 12.6%, χ2=27.307, P<0.001; 2.9% vs. 13.3%, χ2=8.814, P=0.003). TCT results of patients in the two groups indicated that the positive rates of low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) were relatively low, which were 22.1% (23/104) and 24.9% (77/309), respectively, and the differences were not statistically significant (χ2=0.333, P=0.564). Conclusion The clinical symptoms of postmenopausal CIN and CC patients are main vaginal irregular bleeding, contact vaginal bleeding is rare.
[Key words] Postmenopausal; Cervical intraepithelial neoplasia; Cervical cancer; Screening; Clinical features
宮頸癌(CC)是導(dǎo)致女性癌癥相關(guān)死亡的第四大常見原因,據(jù)估計2018年全球約有56.9萬新確診病例,31.1萬人死亡,中國約有10.6萬新確診病例,4.7萬人死亡[1]。正常宮頸上皮可在高危型人乳頭瘤病毒(HPV)感染后3~5年發(fā)展成為高級別宮頸上皮內(nèi)瘤變(CIN2~CIN3),但值得注意的是,在25歲以下的女性中,超過70%的CIN2或CIN3可自行消退[2-4]。CIN2或CIN3進(jìn)一步發(fā)展成為CC需要20~30年,在這漫長的時間內(nèi),可進(jìn)行許多干預(yù)措施,來減少CC的發(fā)病率和死亡率[5-6]。雖然一些研究報告了老年人群中宮頸上皮內(nèi)瘤變(CIN)的發(fā)病率有所下降,但這些研究來自發(fā)達(dá)國家,在這些國家,老年婦女更有可能接受過規(guī)范化的CC篩查。而來自印度的最新數(shù)據(jù)表明,在欠發(fā)達(dá)國家,這種關(guān)系可能會逆轉(zhuǎn),年齡越大,發(fā)生CIN和CC的風(fēng)險越大[7]。據(jù)Wang等[8]報道,2010年中國成年女性CC篩查中,只有1/5的中國女性報告曾接受CC篩查的巴氏涂片。Leach等[9]報道,老年婦女傾向于認(rèn)為更年期可使她們免于婦科疾病,除非有臨床癥狀的困擾,否則不接受巴氏涂片。目前國際研究一致認(rèn)為,CC的晚期診斷與文盲或低教育水平、健康知識缺乏、老年、重度吸煙、酗酒、精神疾病和低社會經(jīng)濟(jì)地位有關(guān)[9]。
因此絕經(jīng)后女性的CC篩查意識不強(qiáng)及絕經(jīng)后女性CC自身的特殊性,使其錯過最佳預(yù)防和治療時機(jī)。本研究對413例CIN及CC患者進(jìn)行回顧性研究,旨在探討絕經(jīng)期CIN及CC患者的臨床特點和CC篩查的重要性。
1資料與方法
1.1 一般資料
選擇2010年12月~2017年8月由安徽醫(yī)科大學(xué)附屬巢湖醫(yī)院收治的413例CIN及CC患者,根據(jù)患者是否絕經(jīng)分為絕經(jīng)組和未絕經(jīng)組,分別為104、309例。絕經(jīng)組年齡45~87歲,平均(61.29±9.80)歲;CIN1 13例,CIN2 8例,CIN3 37例,CC46例。未絕經(jīng)組年齡23~56歲,平均(43.51±6.39)歲;CIN1 55例,CIN2 52例,CIN3 121例,CC81例。兩組均處于國際婦產(chǎn)聯(lián)盟(FIGO)Ⅰ期。所有患者均經(jīng)病理活檢確診。本研究經(jīng)安徽醫(yī)科大學(xué)附屬巢湖醫(yī)院醫(yī)學(xué)倫理委員會審核通過。
1.2 方法
回顧性分析413例CIN及CC患者的臨床資料,包括臨床特點、液基薄層細(xì)胞檢測(TCT)。
1.3 觀察指標(biāo)
分析兩組的臨床特點(接觸性陰道出血、陰道不規(guī)則流血、白帶異常、無明顯癥狀)及TCT結(jié)果。
1.4統(tǒng)計學(xué)方法
采用SPSS 24.0 統(tǒng)計軟件進(jìn)行數(shù)據(jù)處理分析,計量資料以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,采用t檢驗;計數(shù)資料以率表示,采用χ2檢驗,以P<0.05為差異有統(tǒng)計學(xué)意義。
2結(jié)果
2.1兩組臨床特點的比較
絕經(jīng)組和未絕經(jīng)組中,因無明顯癥狀,通過正常體檢發(fā)現(xiàn)宮頸病變占多數(shù),分別占53.8%、68.9%,比較差異有統(tǒng)計學(xué)意義(P=0.005)。絕經(jīng)組臨床特點以陰道不規(guī)則流血為主(35.6%)。接觸性陰道出血明顯少于未絕經(jīng)組,差異有統(tǒng)計學(xué)意義(P=0.003)(表1)。
表1? ?兩組臨床特點的比較[n(%)]
2.2兩組TCT檢查結(jié)果的比較
未絕經(jīng)組中,未見惡性細(xì)胞和上皮病變細(xì)胞(NILM)21例,不能明確診斷意義的不典型鱗狀細(xì)胞(ASC-US)13例,非典型鱗狀細(xì)胞-不除外上皮內(nèi)高度病變(ASC-H)39例,低度鱗狀上皮內(nèi)瘤變(LSIL)49例,高度鱗狀上皮內(nèi)瘤變(HSIL)28例;絕經(jīng)組中分別為8、4、12、17、6例。兩組TCT檢查提示LSIL、HSIL陽性率均較低,未絕經(jīng)組和絕經(jīng)組分別占24.9%(77/309)和22.1%(23/104),差異無統(tǒng)計學(xué)意義(χ2=0.333,P=0.564)。
3討論
本研究結(jié)果顯示,與未絕經(jīng)組比較,絕經(jīng)組通過體檢發(fā)現(xiàn)宮頸病變的占比明顯更少(P<0.05)。絕經(jīng)組以陰道不規(guī)則流血為主要就診原因的患者占比明顯多于未絕經(jīng)組,而絕經(jīng)組以接觸性陰道出血為主要就診原因的患者占比明顯少于未絕經(jīng)組(P<0.05)。兩組TCT檢查提示LSIL、HSIL陽性率均較低。
眾所周知,CC的篩查對降低CC的發(fā)病率和死亡率是有益的。據(jù)Adegoke等[10]報道,通過對SEER(surveillance,epidemiology,and end results)數(shù)據(jù)庫分析發(fā)現(xiàn),在實施CC篩查的35年時間里,美國CC的總發(fā)病率下降了54%,在美國和歐盟等發(fā)達(dá)國家,使用細(xì)胞學(xué)檢查作為CC的篩查手段會明顯降低CC的發(fā)病率,尤其是對絕經(jīng)后的女性[11-12]。但在較不發(fā)達(dá)國家,使用細(xì)胞學(xué)檢查作為主要篩查方法是不可行的[13]。
分析既往關(guān)于CC篩查普及程度的報告,發(fā)現(xiàn)結(jié)果不容樂觀。據(jù)丹麥的一項研究顯示,超過45%的CC患者篩查不足[14]。據(jù)Bao等[15]報道,中國35~64歲女性有26.7%曾接受CC篩查,并且50歲以上的女性篩查覆蓋率明顯低于35~49歲的女性,同時也報道農(nóng)村和中西部女性的篩查覆蓋率低于城市和東部女性。據(jù)Liu等[16]報道,在對我國東部某地區(qū)農(nóng)村進(jìn)行抽樣調(diào)查發(fā)現(xiàn)當(dāng)?shù)嘏詫C的認(rèn)識水平較差,雖然當(dāng)?shù)靥峁┝嗣赓M的CC篩查項目,但篩查率仍然不高。
本研究絕經(jīng)組通過體檢發(fā)現(xiàn)宮頸病變的占比明顯少于未絕經(jīng)組(P<0.05),這或可用絕經(jīng)后女性對體檢意識并沒有未絕經(jīng)女性強(qiáng)來解釋。當(dāng)然體檢意識不強(qiáng)可由多方面原因造成,如年齡、低經(jīng)濟(jì)水平、教育程度低、獲取健康知識的途徑有限、與衛(wèi)生工作者溝通障礙、沒有醫(yī)療保險等[8,17]。
絕經(jīng)后女性因?qū)m頸解剖生理的特殊性,使CC的臨床癥狀或體征有時表現(xiàn)的并不明顯,如在本研究中,絕經(jīng)組CC患者以陰道不規(guī)則流血為主要就診時的臨床表現(xiàn),因?qū)m頸口鱗柱狀交界區(qū)內(nèi)移,絕經(jīng)組接觸性出血僅占2.9%(3/104),據(jù)王冬梅等[18]分析,絕經(jīng)后女性陰道不規(guī)則流血常見病因最主要為炎癥,其次為功能失調(diào)性子宮出血,惡性腫瘤引起的陰道不規(guī)則流血占比卻較小,另外,值得注意的是絕經(jīng)10年后出現(xiàn)陰道不規(guī)則流血,惡性腫瘤的發(fā)病率可達(dá)60%以上。這些無疑給CC的初診帶來更大的迷惑性,入院檢查成本提高,同樣也會給絕經(jīng)后女性帶來意外傷害,如陰道鏡的轉(zhuǎn)診率提高。
目前,TCT已經(jīng)開始普遍用于CC的篩查,其優(yōu)點在于采集到宮頸管細(xì)胞的同時去除了宮頸黏液和炎性細(xì)胞,從而提高宮頸病變的檢出率[19-20]。但梅天瓊等[21]分析,由于絕經(jīng)后女性宮頸管細(xì)胞萎縮的特殊因素存在,使得用TCT可能導(dǎo)致部分患者誤診或漏診。在本研究中,兩組TCT檢查提示LSIL、HSIL陽性率均較低,絕經(jīng)組和未絕經(jīng)組分別占22.1%(23/104)、24.9%(77/309),這與以往文獻(xiàn)報道相似[22]。
當(dāng)然,承認(rèn)本研究也有一定的局限性。首先,由于本研究所在醫(yī)院從2014年才納入HPV檢測,考慮到病例數(shù)較少,并沒有分析TCT檢查聯(lián)合HPV檢測對絕經(jīng)后CC女性的診斷性能是否有所提高。其次,在本研究中,并沒有對絕經(jīng)后女性未參與CC篩查的具體原因進(jìn)行深入調(diào)查,不能很好的解釋絕經(jīng)組以體檢發(fā)現(xiàn)宮頸病變的占比低于未絕經(jīng)組的具體原因。
綜上所述,絕經(jīng)組通過體檢發(fā)現(xiàn)宮頸病變的占比明顯低于未絕經(jīng)組,絕經(jīng)組以陰道不規(guī)則流血為主要就診原因的患者占比明顯多于未絕經(jīng)組,而絕經(jīng)組以接觸性陰道出血為主要就診原因的患者占比明顯少于未絕經(jīng)組。絕經(jīng)組和未絕經(jīng)組TCT檢查提示LSIL、HSIL陽性率均較低??赡軐α私饨^經(jīng)后女性參加CC篩查的重要性提供幫助,并對絕經(jīng)后CC患者的臨床癥狀特點和TCT檢查的診斷性能提出探討。
[參考文獻(xiàn)]
[1]Cancer Today-IARC,World Health Organization,Dec 2018,[Online]. http://gco.iarc.fr/today/fact-sheets-populations
[2]Monteiro DLM, Trajano AJB, ussomano FB,et al.Prognosis of intraepithelial cervical lesion during adolescence in to two years of follow up[J].J Pediatr Adolesc Gynecol,2010,23(4):230-236.
[3]Moscicki AB,Ma Y,Wibbelsman C,et al.Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women[J].Obstet Gynecol,2010,16(6):1373-1380.
[4]Wright JD,Davila Rmpinto KR,Merritt DF,et al.Cervical dysplasia in adolescents[J].Obstet Gynecol,2005,106(1):115-120.
[5]Mccredie MR,Sharples KJ,Paul C,et al.Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3:a retrospective cohort study[J].Lancet Oncol,2008,9(5):425-434.
[6]Vink MA,Bogaards JA,Van Kemenade FJ,et al.Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly Censored National Registry Data[J].Am J Epidemiol,2013,178(7):1161-1169.
[7]Ansari M,Mehdi G,Arif SH,et al.Smear patterns and spectrum of premalignant and malignant cervical epithelial lesions in postmenopausal Indian women:a hospital-based study[J].Diagn Cytopathol,2012, 40(11):976-983.
[8]Wang B,He M,Chao A,et al.Cervical Cancer Screening Among adult women in China,2010[J].Oncologist,2015,20(6):627-634.
[9]Leach CR,Schoenberg NE.The vicious cycle of inadequate early detection: a complementary study on barriers to cervical cancer screening among middle-aged and older women[J].Prev Chronic Dis,2007,4(4):A95.
[10]Adegoke O,Kulasingam S,Virnig B.Cervical cancer trends in the United States: a 35-year population-based analysis[J].J Womens Health (Larchmt),2012,21(10):1031-1037.
[11]Mathew A,George PS.Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide[J].Asian Pac J Cancer Prev,2009,10(4):645-650.
[12]Smith HO,Tiffany MF,Qualls CR,et al.The Rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study[J].Gynecol Oncol,2000,78(2):97-105.
[13]Sankaranarayanan R,Budukh AM,Rajkumar R.Effective screening programmes for cervical cancer in low- and middle-income developing countries[J].Bull World Health Organ,2001,79(10):954-962.
[14]Kirschner B,Poll S,Rygaard C,et al.Screening history in women with cervical cancer in a Danish population-based screening program[J].Gynecol Oncol,2011,120(1):68-72.
[15]Bao HL,Wang LH,Wang LM,et al.Study on the coverage of cervical and breast cancer screening among women aged 35-69 years and related impact of socioeconomic factors in China,2013[J].Zhonghua Liuxingbingxue Zazhi,2018,39(2):208.
[16]Tongtong L,Shunping L,Julie R,et al.Assessing knowledge and attitudes towards cervical cancer screening among rural women in Eastern China[J].Int J Environ Res Public Health,2017,14(9):967.
[17]Nolan J,Renderos TB,Hynson J,et al.Barriers to cervical cancer screening and follow-up care among black women in massachusetts[J].J Obstet Gynecol Neonatal Nurs,2014,43(5):580-588.
[18]王冬梅,侯立文,林榮平,等.323例絕經(jīng)后陰道流血病因分析[J].中國婦幼保健,2007,22(27):3850.
[19]吳冬梅,郭慈仁,余江,等.癌前期病變高危型人乳頭瘤病毒多重感染與宮頸癌及關(guān)系的研究[J].中國醫(yī)藥,2011, 6(5):604-606.
[20]李琴艷,付雯,鄒鵬.宮頸液基細(xì)胞學(xué)檢測與組織病理學(xué)檢測在宮頸病變診斷中的價值[J].中國實驗診斷學(xué),2011, 15(5):879-881.
[21]梅天瓊,鄭麗波,郭玲.宮頸液基細(xì)胞篩查在宮頸癌篩查中的臨床應(yīng)用[J].中國實驗診斷學(xué),2011,15(7):1180-1181.
[22]郝敏,金影,郝增平.絕經(jīng)期與非絕經(jīng)期高級別宮頸上皮內(nèi)瘤變及宮頸癌患者臨床特點分析[J].中國婦產(chǎn)科臨床雜志,2017,18(3):257-258.
(收稿日期:2019-03-07? 本文編輯:崔建中)